ArticleJournal of virology1998
Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 32 citations in OpenAlex.
- Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Conditional gene expression systems to study herpesvirus biology in vivo.Medical microbiology and immunology · 2008Review
- Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.Journal of virology · 2002Article
- Specific deletion of autoreactive T cells by adenovirus-transfected, Fas ligand-producing antigen-presenting cells.Immunologic research · 2002Review
- Efficient gene activation in cultured mammalian cells mediated by FLP recombinase-expressing recombinant adenovirus.Nucleic acids research · 2001Article
- Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system.Gene therapy · 2000Article
- Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice.The Journal of clinical investigation · 2000Article
- Immune responses to adenovirus and adeno-associated virus in humans.Gene therapy · 1999Article
- Adenovirus-mediated gene expression in vivo is enhanced by the antiapoptotic bcl-2 gene.Journal of virology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 4 countries.
Funding
Abstract
An adenovirus vector encoding murine Fas ligand (mFasL) under an inducible control was derived. In vivo ectopic expression of mFasL in murine livers induced an inflammatory cellular infiltration. Furthermore, ectopic expression of mFasL by myocytes did not allow prolonged vector-mediated transgene expression. Thus, ectopic expression of functional mFasL in vector-transduced cells does not appear to confer, by itself, an immunoprivileged site sufficient to mitigate adenovirus vector immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.